VEVYE® (cyclosporine ophthalmic solution) 0.1% is FDA-Approved. It is indicated for the treatment of the signs and symptoms of dry eye disease. VEVYE is the first and only cyclosporine dissolved in a semifluorinated alkane.
VEVYE is
water-free
preservative-free
osmolarity free
pH free
For more information, please click here to visit www.vevye.com.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.
Adverse Reactions
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE®, please see the Full Prescribing Information.